Big Pharma making a *killing* on US bioterror threats

[Guest guest]

Thank you, and members please comment. Let me talk about the vaccines first. I have NO doubt that most of these vaccines are entirely ineffective and likely to cause serious disease or even death- my family and I represent several victims amidst a haze of med and gov lies. But, is it correct to say that in some cases the theory (and procedure) is sound... I'm not talking about polio, but I am talking about smallpox - this is (was) a very nasty disease - was it not prudent to use the vaccine, and did it not help eradicate the disease? And yet, since it has supposedly been eradicated, then why do we continue to vaccinate everyone in sight for smallpox?

2nd, after I've entered a state of pure horror over the extent of medical and gov fraud and the extent to which I've been victimized, I've jointed the fray of those writing in to Obama's camp. Most of the comments there seem horribly naive, unaware that the med industry is the worst blight and horrific contagion in human history... I've written two emails demanding an end to mercury or similar toxic ingredients in a wide range of materials, but doubt anyone notices in the sea of comments like, "gee whiz, medical care costs too much..." So, anyone who wants to try, go here, http://change.gov/newsroom/entry/join_the_discussion_daschles_healthcare_response/

Thank you... Alan Foos

From: Viviane Lerner <vivlerner@...>Subject: Big Pharma making a *killing* on US bioterror threats"NO FORCED VACCINATION" <no-forced-vaccination >Cc: "NATURAL NEWS" <insider@...>Date: Tuesday, December 2, 2008, 10:20 PM

Also

http://snipurl. com/729h2 [www_in-pharmatechn ologist_com]

Danish biopharma to supply 20 million smallpox vaccines to US

By Katrina Megget, 05-Jun-2007

Related topics: Industry Drivers, Contract services (outsourcing)

Denmark-based Bavarian Nordic has clocked up a whopping $500m (¤371m) contract with the US government to supply millions of doses of smallpox vaccine.

The five-year contract will see the biopharmaceutical company supplying 20 million doses of its smallpox vaccine, Imvamune to the Strategic National Stockpile for individuals to be considered "at risk", such as those who are immuno-compromised.

The total deal with the US Department of Health and Human Services (HHS) could be extended to be worth $1.5bn, which would include further clinical studies to extend the license to include people infected with HIV, children and the elderly, as well as procurement of up to an additional 60 million doses of the vaccine.

========http://www.medicaln ewstoday. com/articles/ 131292.php

The Government Of Canada Procures IMVAMUNE® Smallpox Vaccine For The Country's Biological Preparedness

01 Dec 2008

Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE®.

The Canadian authorities intend to use IMVAMUNE® as part of the country's bio-preparedness programme.

The contract provides for the delivery of 20,000 doses of IMVAMUNE® and payment for the application process to support the use of IMVAMUNE® in an emergency under the Canadian Government's Special Access Programme. The delivery will take place in 2009.

The contract also provides for the optional purchase of an additional 180,000 doses of IMVAMUNE® as well as payment for investigating the requirements for obtaining a licensure of the vaccine in Canada. Hereby, the Government of Canada and Bavarian Nordic have entered into a long term contract.

The order does not change Bavarian Nordic's previously announced financial guidance for 2008.

Smallpox and the need for a new vaccine

Smallpox is the most dangerous infectious disease ever faced by mankind. Hundreds of millions of people have died from the disease. Today, the smallpox threat may be encountered in various ways: bio-terrorism, synthetically manufactured viruses and outbreak from controlled smallpox stocks.

The old, conventional smallpox vaccines which have been stockpiled around the world are not suited to current needs. They are not safe and may cause severe side effects, even death. These vaccines cannot be given to people who are immune compromised, which constitute approx. 25 % of the population.

IMVAMUNE®, Bavarian Nordic's new, third generation smallpox vaccine, offers a number of unique advantages compared to the old vaccines. The superior safety profile of IMVAMUNE® makes it suitable for vaccination of those with compromised immunity. Furthermore, the vaccine is easier to administer and it protects faster than the old vaccines, which is convenient for use in the general population in the case of an emergency.

According to Anders Hedegaard, President & CEO of Bavarian Nordic, "With the Canadian contract, yet another nation recognizes IMVAMUNE® as an essential part of the its smallpox preparedness. Furthermore Bavarian Nordic has just received a small follow-up order with the same Asian country under the same contractual framework as in March. This further demonstrates that countries are increasingly focused on building and retaining an optimum biological preparedness against smallpox, the world's most feared and dangerous infectious disease. With IMVAMUNE® these countries have gained access to the most innovative smallpox vaccine available."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN® is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE®.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

Bavarian Nordic

=====

In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

[Guest guest]

Thank you, and members please comment. Let me talk about the vaccines first. I have NO doubt that most of these vaccines are entirely ineffective and likely to cause serious disease or even death- my family and I represent several victims amidst a haze of med and gov lies. But, is it correct to say that in some cases the theory (and procedure) is sound... I'm not talking about polio, but I am talking about smallpox - this is (was) a very nasty disease - was it not prudent to use the vaccine, and did it not help eradicate the disease? And yet, since it has supposedly been eradicated, then why do we continue to vaccinate everyone in sight for smallpox?

2nd, after I've entered a state of pure horror over the extent of medical and gov fraud and the extent to which I've been victimized, I've jointed the fray of those writing in to Obama's camp. Most of the comments there seem horribly naive, unaware that the med industry is the worst blight and horrific contagion in human history... I've written two emails demanding an end to mercury or similar toxic ingredients in a wide range of materials, but doubt anyone notices in the sea of comments like, "gee whiz, medical care costs too much..." So, anyone who wants to try, go here, http://change.gov/newsroom/entry/join_the_discussion_daschles_healthcare_response/

Thank you... Alan Foos

From: Viviane Lerner <vivlerner@...>Subject: Big Pharma making a *killing* on US bioterror threats"NO FORCED VACCINATION" <no-forced-vaccination >Cc: "NATURAL NEWS" <insider@...>Date: Tuesday, December 2, 2008, 10:20 PM

Also

http://snipurl. com/729h2 [www_in-pharmatechn ologist_com]

Danish biopharma to supply 20 million smallpox vaccines to US

By Katrina Megget, 05-Jun-2007

Related topics: Industry Drivers, Contract services (outsourcing)

Denmark-based Bavarian Nordic has clocked up a whopping $500m (¤371m) contract with the US government to supply millions of doses of smallpox vaccine.

The five-year contract will see the biopharmaceutical company supplying 20 million doses of its smallpox vaccine, Imvamune to the Strategic National Stockpile for individuals to be considered "at risk", such as those who are immuno-compromised.

The total deal with the US Department of Health and Human Services (HHS) could be extended to be worth $1.5bn, which would include further clinical studies to extend the license to include people infected with HIV, children and the elderly, as well as procurement of up to an additional 60 million doses of the vaccine.

========http://www.medicaln ewstoday. com/articles/ 131292.php

The Government Of Canada Procures IMVAMUNE® Smallpox Vaccine For The Country's Biological Preparedness

01 Dec 2008

Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE®.

The Canadian authorities intend to use IMVAMUNE® as part of the country's bio-preparedness programme.

The contract provides for the delivery of 20,000 doses of IMVAMUNE® and payment for the application process to support the use of IMVAMUNE® in an emergency under the Canadian Government's Special Access Programme. The delivery will take place in 2009.

The contract also provides for the optional purchase of an additional 180,000 doses of IMVAMUNE® as well as payment for investigating the requirements for obtaining a licensure of the vaccine in Canada. Hereby, the Government of Canada and Bavarian Nordic have entered into a long term contract.

The order does not change Bavarian Nordic's previously announced financial guidance for 2008.

Smallpox and the need for a new vaccine

Smallpox is the most dangerous infectious disease ever faced by mankind. Hundreds of millions of people have died from the disease. Today, the smallpox threat may be encountered in various ways: bio-terrorism, synthetically manufactured viruses and outbreak from controlled smallpox stocks.

The old, conventional smallpox vaccines which have been stockpiled around the world are not suited to current needs. They are not safe and may cause severe side effects, even death. These vaccines cannot be given to people who are immune compromised, which constitute approx. 25 % of the population.

IMVAMUNE®, Bavarian Nordic's new, third generation smallpox vaccine, offers a number of unique advantages compared to the old vaccines. The superior safety profile of IMVAMUNE® makes it suitable for vaccination of those with compromised immunity. Furthermore, the vaccine is easier to administer and it protects faster than the old vaccines, which is convenient for use in the general population in the case of an emergency.

According to Anders Hedegaard, President & CEO of Bavarian Nordic, "With the Canadian contract, yet another nation recognizes IMVAMUNE® as an essential part of the its smallpox preparedness. Furthermore Bavarian Nordic has just received a small follow-up order with the same Asian country under the same contractual framework as in March. This further demonstrates that countries are increasingly focused on building and retaining an optimum biological preparedness against smallpox, the world's most feared and dangerous infectious disease. With IMVAMUNE® these countries have gained access to the most innovative smallpox vaccine available."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN® is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE®.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

Bavarian Nordic

=====

In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

[Guest guest]

Thank you, and members please comment. Let me talk about the vaccines first. I have NO doubt that most of these vaccines are entirely ineffective and likely to cause serious disease or even death- my family and I represent several victims amidst a haze of med and gov lies. But, is it correct to say that in some cases the theory (and procedure) is sound... I'm not talking about polio, but I am talking about smallpox - this is (was) a very nasty disease - was it not prudent to use the vaccine, and did it not help eradicate the disease? And yet, since it has supposedly been eradicated, then why do we continue to vaccinate everyone in sight for smallpox?

2nd, after I've entered a state of pure horror over the extent of medical and gov fraud and the extent to which I've been victimized, I've jointed the fray of those writing in to Obama's camp. Most of the comments there seem horribly naive, unaware that the med industry is the worst blight and horrific contagion in human history... I've written two emails demanding an end to mercury or similar toxic ingredients in a wide range of materials, but doubt anyone notices in the sea of comments like, "gee whiz, medical care costs too much..." So, anyone who wants to try, go here, http://change.gov/newsroom/entry/join_the_discussion_daschles_healthcare_response/

Thank you... Alan Foos

From: Viviane Lerner <vivlerner@...>Subject: Big Pharma making a *killing* on US bioterror threats"NO FORCED VACCINATION" <no-forced-vaccination >Cc: "NATURAL NEWS" <insider@...>Date: Tuesday, December 2, 2008, 10:20 PM

Also

http://snipurl. com/729h2 [www_in-pharmatechn ologist_com]

Danish biopharma to supply 20 million smallpox vaccines to US

By Katrina Megget, 05-Jun-2007

Related topics: Industry Drivers, Contract services (outsourcing)

Denmark-based Bavarian Nordic has clocked up a whopping $500m (¤371m) contract with the US government to supply millions of doses of smallpox vaccine.

The five-year contract will see the biopharmaceutical company supplying 20 million doses of its smallpox vaccine, Imvamune to the Strategic National Stockpile for individuals to be considered "at risk", such as those who are immuno-compromised.

The total deal with the US Department of Health and Human Services (HHS) could be extended to be worth $1.5bn, which would include further clinical studies to extend the license to include people infected with HIV, children and the elderly, as well as procurement of up to an additional 60 million doses of the vaccine.

========http://www.medicaln ewstoday. com/articles/ 131292.php

The Government Of Canada Procures IMVAMUNE® Smallpox Vaccine For The Country's Biological Preparedness

01 Dec 2008

Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE®.

The Canadian authorities intend to use IMVAMUNE® as part of the country's bio-preparedness programme.

The contract provides for the delivery of 20,000 doses of IMVAMUNE® and payment for the application process to support the use of IMVAMUNE® in an emergency under the Canadian Government's Special Access Programme. The delivery will take place in 2009.

The contract also provides for the optional purchase of an additional 180,000 doses of IMVAMUNE® as well as payment for investigating the requirements for obtaining a licensure of the vaccine in Canada. Hereby, the Government of Canada and Bavarian Nordic have entered into a long term contract.

The order does not change Bavarian Nordic's previously announced financial guidance for 2008.

Smallpox and the need for a new vaccine

Smallpox is the most dangerous infectious disease ever faced by mankind. Hundreds of millions of people have died from the disease. Today, the smallpox threat may be encountered in various ways: bio-terrorism, synthetically manufactured viruses and outbreak from controlled smallpox stocks.

The old, conventional smallpox vaccines which have been stockpiled around the world are not suited to current needs. They are not safe and may cause severe side effects, even death. These vaccines cannot be given to people who are immune compromised, which constitute approx. 25 % of the population.

IMVAMUNE®, Bavarian Nordic's new, third generation smallpox vaccine, offers a number of unique advantages compared to the old vaccines. The superior safety profile of IMVAMUNE® makes it suitable for vaccination of those with compromised immunity. Furthermore, the vaccine is easier to administer and it protects faster than the old vaccines, which is convenient for use in the general population in the case of an emergency.

According to Anders Hedegaard, President & CEO of Bavarian Nordic, "With the Canadian contract, yet another nation recognizes IMVAMUNE® as an essential part of the its smallpox preparedness. Furthermore Bavarian Nordic has just received a small follow-up order with the same Asian country under the same contractual framework as in March. This further demonstrates that countries are increasingly focused on building and retaining an optimum biological preparedness against smallpox, the world's most feared and dangerous infectious disease. With IMVAMUNE® these countries have gained access to the most innovative smallpox vaccine available."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN® is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE®.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

Bavarian Nordic

=====

In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

[Guest guest]

Thank you, and members please comment. Let me talk about the vaccines first. I have NO doubt that most of these vaccines are entirely ineffective and likely to cause serious disease or even death- my family and I represent several victims amidst a haze of med and gov lies. But, is it correct to say that in some cases the theory (and procedure) is sound... I'm not talking about polio, but I am talking about smallpox - this is (was) a very nasty disease - was it not prudent to use the vaccine, and did it not help eradicate the disease? And yet, since it has supposedly been eradicated, then why do we continue to vaccinate everyone in sight for smallpox?

2nd, after I've entered a state of pure horror over the extent of medical and gov fraud and the extent to which I've been victimized, I've jointed the fray of those writing in to Obama's camp. Most of the comments there seem horribly naive, unaware that the med industry is the worst blight and horrific contagion in human history... I've written two emails demanding an end to mercury or similar toxic ingredients in a wide range of materials, but doubt anyone notices in the sea of comments like, "gee whiz, medical care costs too much..." So, anyone who wants to try, go here, http://change.gov/newsroom/entry/join_the_discussion_daschles_healthcare_response/

Thank you... Alan Foos

From: Viviane Lerner <vivlerner@...>Subject: Big Pharma making a *killing* on US bioterror threats"NO FORCED VACCINATION" <no-forced-vaccination >Cc: "NATURAL NEWS" <insider@...>Date: Tuesday, December 2, 2008, 10:20 PM

Also

http://snipurl. com/729h2 [www_in-pharmatechn ologist_com]

Danish biopharma to supply 20 million smallpox vaccines to US

By Katrina Megget, 05-Jun-2007

Related topics: Industry Drivers, Contract services (outsourcing)

Denmark-based Bavarian Nordic has clocked up a whopping $500m (¤371m) contract with the US government to supply millions of doses of smallpox vaccine.

The five-year contract will see the biopharmaceutical company supplying 20 million doses of its smallpox vaccine, Imvamune to the Strategic National Stockpile for individuals to be considered "at risk", such as those who are immuno-compromised.

The total deal with the US Department of Health and Human Services (HHS) could be extended to be worth $1.5bn, which would include further clinical studies to extend the license to include people infected with HIV, children and the elderly, as well as procurement of up to an additional 60 million doses of the vaccine.

========http://www.medicaln ewstoday. com/articles/ 131292.php

The Government Of Canada Procures IMVAMUNE® Smallpox Vaccine For The Country's Biological Preparedness

01 Dec 2008

Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE®.

The Canadian authorities intend to use IMVAMUNE® as part of the country's bio-preparedness programme.

The contract provides for the delivery of 20,000 doses of IMVAMUNE® and payment for the application process to support the use of IMVAMUNE® in an emergency under the Canadian Government's Special Access Programme. The delivery will take place in 2009.

The contract also provides for the optional purchase of an additional 180,000 doses of IMVAMUNE® as well as payment for investigating the requirements for obtaining a licensure of the vaccine in Canada. Hereby, the Government of Canada and Bavarian Nordic have entered into a long term contract.

The order does not change Bavarian Nordic's previously announced financial guidance for 2008.

Smallpox and the need for a new vaccine

Smallpox is the most dangerous infectious disease ever faced by mankind. Hundreds of millions of people have died from the disease. Today, the smallpox threat may be encountered in various ways: bio-terrorism, synthetically manufactured viruses and outbreak from controlled smallpox stocks.

The old, conventional smallpox vaccines which have been stockpiled around the world are not suited to current needs. They are not safe and may cause severe side effects, even death. These vaccines cannot be given to people who are immune compromised, which constitute approx. 25 % of the population.

IMVAMUNE®, Bavarian Nordic's new, third generation smallpox vaccine, offers a number of unique advantages compared to the old vaccines. The superior safety profile of IMVAMUNE® makes it suitable for vaccination of those with compromised immunity. Furthermore, the vaccine is easier to administer and it protects faster than the old vaccines, which is convenient for use in the general population in the case of an emergency.

According to Anders Hedegaard, President & CEO of Bavarian Nordic, "With the Canadian contract, yet another nation recognizes IMVAMUNE® as an essential part of the its smallpox preparedness. Furthermore Bavarian Nordic has just received a small follow-up order with the same Asian country under the same contractual framework as in March. This further demonstrates that countries are increasingly focused on building and retaining an optimum biological preparedness against smallpox, the world's most feared and dangerous infectious disease. With IMVAMUNE® these countries have gained access to the most innovative smallpox vaccine available."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN® is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE®.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

Bavarian Nordic

=====

In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.